Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Share-based Compensation (2018 - 2025)

Historic Share-based Compensation for Inmune Bio (INMB) over the last 8 years, with Q3 2025 value amounting to $3.0 million.

  • Inmune Bio's Share-based Compensation rose 7358.93% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.4 million, marking a year-over-year increase of 824.61%. This contributed to the annual value of $7.6 million for FY2024, which is 321.66% up from last year.
  • According to the latest figures from Q3 2025, Inmune Bio's Share-based Compensation is $3.0 million, which was up 7358.93% from $1.5 million recorded in Q2 2025.
  • Inmune Bio's Share-based Compensation's 5-year high stood at $3.0 million during Q3 2025, with a 5-year trough of $769000.0 in Q2 2021.
  • Over the past 5 years, Inmune Bio's median Share-based Compensation value was $1.8 million (recorded in 2024), while the average stood at $1.8 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first plummeted by 4569.87% in 2021, then skyrocketed by 14707.41% in 2022.
  • Over the past 5 years, Inmune Bio's Share-based Compensation (Quarter) stood at $1.5 million in 2021, then rose by 16.91% to $1.7 million in 2022, then grew by 6.8% to $1.9 million in 2023, then fell by 5.94% to $1.8 million in 2024, then surged by 69.83% to $3.0 million in 2025.
  • Its Share-based Compensation was $3.0 million in Q3 2025, compared to $1.5 million in Q2 2025 and $2.1 million in Q1 2025.